H.R. 749: Lower Drug Costs through Competition Act

Before you vote › Federal bills

H.R. 749: Lower Drug Costs through Competition Act

115th Congress · introduced 2017-01-30 · Health · Latest: Referred to the Subcommittee on Health.

federal

Save to my notebook What does this mean? Print

Official title

Lower Drug Costs through Competition Act

Plain summary

Lower Drug Costs through Competition Act This bill amends the Federal Food, Drug, and Cosmetic Act to revise provisions regarding review and approval of generic drug applications or supplements to generic drug applications for drugs: (1) for which there is a shortage, or (2) that have not been recently introduced to the market by more than one manufacturer and for which tentative approval has not been granted to more than two applications. The Food and Drug Administration (FDA) must prioritize the review of such submissions and act on them within 180 days. The FDA may expedite the inspection of a facility proposed to manufacture such a drug. Beginning FY2019, the FDA must award a transferrable generic drug priority review voucher to the sponsor of such an application once the drug has a sustained market presence. A voucher may be used to have the FDA review and take action upon a generic drug application within 180 days of submission. The FDA must establish an additional user fee for applications subject to a voucher. This voucher program is terminated at the start of FY2024. The FDA must periodically report on generic drug applications filed before FY2018 that are still pending. For a new drug application to be eligible for a priority review voucher as a tropical disease product application, the application must include new, essential clinical investigations. The Government Accountability Office must study the FDA's program for drug risk evaluation and mitigation strategies.

Congressional Research Service summary (Introduced in House), quoted unchanged (nonpartisan). Read the source.

What a vote does

PSI Sci description of the legislative step (not an opinion).

The strongest published arguments

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

How did my representative vote? · This bill's floor votes

Officials and money

Sponsor: Rep. Schrader, Kurt [D-OR-5] · 24 cosponsors

Cost estimate: No cost estimate published yet.

Cosponsors on this site

Gus M. Bilirakis (R-FL), Seth Moulton (D-MA), Ami Bera (D-CA), Jim Costa (D-CA), Scott H. Peters (D-CA), Brett Guthrie (R-KY), Henry Cuellar (D-TX), Darren Soto (D-FL), Sanford D. Bishop, Jr. (D-GA), Bradley Scott Schneider (D-IL), Don Bacon (R-NE), Josh Gottheimer (D-NJ)

No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.

Sources

• Congressional Research Service summary (Introduced in House)
• Congress.gov
• Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-115hr749.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/115/hr>

Record fed-us-cong115-hr749 · catalog fed-us-congress-bills-cong115 · updated 2026-11-15 by psicol fed-bills-cong115